Table 2.

Ongoing clinical trials with immunotherapy in GC.

Rank	NCT Number	Title	Conditions	Interventions	Phases	Completion Date
1	NCT04889768	HIPEC Combined with Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis	Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery	Drug: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery	Not Applicable	July 31, 2025
2	NCT04694183	The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer	Gastric Cancer	Drug: Paclitaxel + S-1 + anti-PD-1 antibody (Peritoneal metastasis) |Drug: SOX regimen + anti-PD-1 antibody (Liver metastasis, para-aortic lymph node metastasis)	Phase 2	November 17, 2022
3	NCT03682744	CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)	Peritoneal Carcinomatosis|Peritoneal Metastases|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreas Cancer|Carcinoembryonic Antigen	Biological: anti-CEA CAR-T cells	Phase 1	March 2021
4	NCT03252938	Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors	Solid Tumors|Peritoneal Carcinomatosis	Drug: IMP321|Drug: Avelumab	Phase 1	June 30, 2024
5	NCT01784900	Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab	Patients With Gastric Peritoneal Carcinomatosis	Drug: Catumaxomab 100 µg|Drug: Catumaxomab 140 µg	Phase 2	January 2016